Spots Global Cancer Trial Database for tnbc
Every month we try and update this database with for tnbc cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Phase II Study Evaluating the Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Chemotherapy as First-line Treatment for Participants With Advanced Triple Negative Breast Cancer | NCT05809895 | Triple Negative... | Ociperlimab Tislelizumab Paclitaxel Nab-paclitaxel Carboplatin Placebo Pembrolizumab Gemcitabine | 18 Years - | Novartis | |
| Study of Eribulin in Combination With Anti-PD-1 Antibody in Patients With Metastatic Triple-Negative Breast Cancer | NCT05402722 | TNBC - Triple-N... | Eribulin anti-PD-1 antib... | 18 Years - 75 Years | Beijing 302 Hospital | |
| Phase II Study Evaluating the Efficacy and Safety of Ociperlimab in Combination With Tislelizumab and Chemotherapy as First-line Treatment for Participants With Advanced Triple Negative Breast Cancer | NCT05809895 | Triple Negative... | Ociperlimab Tislelizumab Paclitaxel Nab-paclitaxel Carboplatin Placebo Pembrolizumab Gemcitabine | 18 Years - | Novartis | |
| Folate Receptor Alpha Peptide Vaccine With GM-CSF in Patients With Triple Negative Breast Cancer | NCT02593227 | Breast Cancer | Low dose FRα va... Cyclophosphamid... High dose FRα v... | 18 Years - | Marker Therapeutics, Inc. | |
| A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer | NCT03742102 | Triple Negative... | Durvalumab Capivasertib Oleclumab Paclitaxel Trastuzumab der... Datopotamab der... | 18 Years - 130 Years | AstraZeneca | |
| Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK | NCT06358573 | Triple-negative... TNBC - Triple-N... | INT230-6 neoadjuvant imm... | 18 Years - | Swiss Group for Clinical Cancer Research | |
| A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer | NCT03901469 | Triple Negative... | ZEN003694 Talazoparib | 18 Years - | Zenith Epigenetics | |
| A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. | NCT06022029 | Triple Negative... Diffuse Large B... Follicular Lymp... Lymphoma, Non-H... Mantle Cell Lym... Bladder Cancer Uveal Melanoma,... Cervix Cancer Carcinoma in Si... Head and Neck S... Skin Cancer Metastatic Canc... Tumor, Solid Tumor Recurrenc... | ONM-501 Cemiplimab | 18 Years - | OncoNano Medicine, Inc. | |
| SHR-A1921 Combined With Bevacizumab in Triple-negative Breast Cancer With Brain Metastases | NCT06210438 | TNBC Brain Metastasi... | SHR-A1921 + Bev... | 18 Years - | Fudan University | |
| Tivozanib in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer | NCT01745367 | Triple Negative... | Tivozanib Hydro... paclitaxel Placebo | 18 Years - | AVEO Pharmaceuticals, Inc. | |
| Evaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitabine and Atezolizumab in Breast Cancer | NCT04739670 | Metastatic Trip... | Atezolizumab Bevacizumab Gemcitabine Carboplatin | 18 Years - 100 Years | Peter MacCallum Cancer Centre, Australia | |
| A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors | NCT05581004 | Locally Advance... NSCLC HNSCC Melanoma TNBC Esophageal Canc... Gastric Cancer Cervical Cancer Urothelial Carc... Clear Cell RCC HCC | RO7502175 Atezolizumab | 18 Years - | Genentech, Inc. | |
| Leronlimab (PRO 140) Combined With Carboplatin in Patients With CCR5+ mTNBC | NCT03838367 | Triple Negative... | 350 mg leronlim... 525 mg leronlim... 700 mg leronlim... AUC 5 Carboplat... Maximum Tolerat... | 18 Years - | CytoDyn, Inc. | |
| Study of Temsirolimus, Erlotinib and Cisplatin in Solid Tumors | NCT00998036 | Triple Negative... | Temsirolimus Cisplatin Erlotinib | 18 Years - | Columbia University | |
| A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. | NCT06022029 | Triple Negative... Diffuse Large B... Follicular Lymp... Lymphoma, Non-H... Mantle Cell Lym... Bladder Cancer Uveal Melanoma,... Cervix Cancer Carcinoma in Si... Head and Neck S... Skin Cancer Metastatic Canc... Tumor, Solid Tumor Recurrenc... | ONM-501 Cemiplimab | 18 Years - | OncoNano Medicine, Inc. | |
| An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC. | NCT04395989 | TNBC - Triple-N... | A1: Pyrotinib w... A2: nab-paclita... B1: everolimus ... B2: nab-paclita... C1: PD-1 with n... C2: nab-paclita... D1: VEGFR and n... D2: nab-paclita... E1: everolimus ... E2: nab-paclita... | 18 Years - 70 Years | Fudan University | |
| A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers | NCT05544929 | Carcinoma, Non-... Cutaneous Melan... Carcinoma, Rena... Carcinoma, Ovar... Nasopharyngeal ... Carcinoma, Thym... Anal Cancer Mesothelioma Esophagogastric... High Microsatel... Squamous Cell C... Triple Negative... | KFA115 pembrolizumab | 18 Years - | Novartis | |
| A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat | NCT02890069 | Colorectal Canc... | PDR001 LCL161 Everolimus Panobinostat QBM076 HDM201 | 18 Years - | Novartis | |
| A Study of SGN-B7H4V in Advanced Solid Tumors | NCT05194072 | Ovarian Neoplas... Peritoneal Neop... Fallopian Tube ... Triple Negative... HER2 Negative B... Hormone Recepto... Endometrial Neo... Carcinoma, Non-... Cholangiocarcin... Gallbladder Car... Adenoid Cystic ... | SGN-B7H4V | 18 Years - | Seagen Inc. | |
| LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer | NCT06387628 | TNBC - Triple-N... | LM-108 Toripalimab Eribulin Nab paclitaxel | 18 Years - 75 Years | Fudan University | |
| A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors | NCT05537740 | Advanced Solid ... | BAY3375968 Pembrolizumab | 18 Years - | Bayer | |
| Evaluation of Pharmacodynamic Effects of IT-pIL12-EP in Patients With TNBC | NCT02531425 | ER-Negative PR-... | IT-pIL12-EP | 18 Years - | OncoSec Medical Incorporated | |
| Study of Adagloxad Simolenin (OBI-822)/OBI-821 in the Adjuvant Treatment of Patients With Globo H Positive TNBC | NCT03562637 | Triple Negative... | adagloxad simol... Globo H IHC Ass... Standard of car... | 18 Years - | OBI Pharma, Inc | |
| Vaccination of Triple Negative Breast Cancer Patients | NCT02938442 | Triple Negative... Breast Neoplasm... | P10s-PADRE with... Doxorubicin + C... | 18 Years - | University of Arkansas | |
| A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat | NCT02890069 | Colorectal Canc... | PDR001 LCL161 Everolimus Panobinostat QBM076 HDM201 | 18 Years - | Novartis | |
| Defining the Triple Negative Breast Cancer Kinome Response to GSK1120212 | NCT01467310 | Breast Cancer | GSK1120212 | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Neoadjuvant Pembrolizumab(Pbr)/Nab-Paclitaxel Followed by Pbr/Epirubicin/Cyclophosphamide in TNBC | NCT03289819 | Malignant Neopl... | Pembrolizumab nab-paclitaxel Epirubicin Cyclophosphamid... | 18 Years - | Institut fuer Frauengesundheit | |
| A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors | NCT04577963 | Triple Negative... Endometrial Can... Solid Tumor, Un... Colorectal Canc... | Fruquintinib Tislelizumab | 18 Years - | Hutchmed | |
| FUSCC Refractory TNBC Platform Study (FUTURE2.0) | NCT05749588 | Triple-negative... | A1: SHR-A1811 A2: SHR-A1811 w... B1: TROP2 ADC B2: TROP2 ADC w... C1: SHR-A1811 C2: SHR-A1811 w... D1: TROP2 ADC D2: TROP2 ADC w... E1: SHR-A1811 F1: TROP2 ADC G1: SHR-A1811 H1: TROP2 ADC | 18 Years - | Fudan University | |
| NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III) | NCT06081244 | Triple Negative... | Sacituzumab gov... Pembrolizumab | 18 Years - | West German Study Group | |
| A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors | NCT05581004 | Locally Advance... NSCLC HNSCC Melanoma TNBC Esophageal Canc... Gastric Cancer Cervical Cancer Urothelial Carc... Clear Cell RCC HCC | RO7502175 Atezolizumab | 18 Years - | Genentech, Inc. | |
| A Beta-only IL-2 ImmunoTherapY Study | NCT05086692 | Advanced Solid ... Unresectable So... Clear Cell Rena... Triple Negative... Non-Small Cell ... Non-Small Cell ... Colorectal Canc... Gastric Cancer Cervical Cancer Basal Cell Carc... Bladder Cancer Merkel Cell Car... Squamous Cell C... Cutaneous Squam... Pleural Mesothe... Esophageal Canc... Endometrial Car... Solid Tumor Solid Tumor, Ad... MSI-H Solid Mal... Cancer With A H... Epithelial Ovar... Primary Periton... Gastroesophagea... Acral Melanoma Mucosal Melanom... Cutaneous Melan... DMMR Solid Mali... Fallopian Tube ... Ovarian Cancer MSI-H Cancer DMMR Cancer Pancreas Adenoc... Skin Cancer | MDNA11 Pembrolizumab | 18 Years - | Medicenna Therapeutics, Inc. | |
| A Study of PM8002 Plus Nab-paclitaxel as First Line Therapy for TNBC | NCT05918133 | TNBC | PM8002 nab-paclitaxel | 18 Years - 75 Years | Biotheus Inc. | |
| A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer | NCT04254107 | Non-small Cell ... Gastric Carcino... Gastroesophagea... Classical Hodgk... Diffuse Large B... Peripheral T-ce... Cutaneous Melan... Head and Neck S... Bladder Cancer Ovarian Cancer Triple Negative... Cervical Cancer | SEA-TGT sasanlimab brentuximab ved... | 18 Years - | Seagen Inc. | |
| A Study to Evaluate Gemcitabine Plus Cisplatin in the Treatment of TNBC Patients Following Neoadjuvant Chemotherapy | NCT04297267 | Triple Negative... | Gemcitabine Cisplatin | 18 Years - 70 Years | Fudan University | |
| Study of Temsirolimus, Erlotinib and Cisplatin in Solid Tumors | NCT00998036 | Triple Negative... | Temsirolimus Cisplatin Erlotinib | 18 Years - | Columbia University | |
| Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC) | NCT05128734 | Breast Cancer T... | Temozolomide Olaparib | 18 Years - | AHS Cancer Control Alberta | |
| Leronlimab (PRO 140) Combined With Carboplatin in Patients With CCR5+ mTNBC | NCT03838367 | Triple Negative... | 350 mg leronlim... 525 mg leronlim... 700 mg leronlim... AUC 5 Carboplat... Maximum Tolerat... | 18 Years - | CytoDyn, Inc. | |
| An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC. | NCT04395989 | TNBC - Triple-N... | A1: Pyrotinib w... A2: nab-paclita... B1: everolimus ... B2: nab-paclita... C1: PD-1 with n... C2: nab-paclita... D1: VEGFR and n... D2: nab-paclita... E1: everolimus ... E2: nab-paclita... | 18 Years - 70 Years | Fudan University | |
| A Study of SGN-PDL1V in Advanced Solid Tumors | NCT05208762 | Carcinoma, Non-... Squamous Cell C... Esophageal Squa... Ovarian Neoplas... Melanoma Triple Negative... Gastric Cancer | SGN-PDL1V pembrolizumab | 18 Years - | Seagen Inc. | |
| Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer | NCT01938638 | Neoplasms | BAY1143572 | 21 Years - | Bayer | |
| Evaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitabine and Atezolizumab in Breast Cancer | NCT04739670 | Metastatic Trip... | Atezolizumab Bevacizumab Gemcitabine Carboplatin | 18 Years - 100 Years | Peter MacCallum Cancer Centre, Australia | |
| A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies | NCT03329950 | Melanoma Non-small Cell ... Breast Cancer Gastric Cancer Renal Cell Carc... Ovarian Cancer Cholangiocarcin... Bladder Urothel... Pancreatic Aden... Colorectal Canc... Esophageal Canc... Hepatic Cancer Head and Neck C... Primary Periton... Fallopian Tube ... Other Solid Tum... Diffuse Large B... Mantle Cell Lym... Indolent B-cell... Non-Hodgkin Lym... Follicular Lymp... Lymphoplasmacyt... Waldenstrom's D... Marginal Zone L... Mucosa Associat... Small Lymphocyt... | CDX-1140 CDX-301 pembrolizumab Chemotherapy | 18 Years - | Celldex Therapeutics | |
| Vaccination of Triple Negative Breast Cancer Patients | NCT02938442 | Triple Negative... Breast Neoplasm... | P10s-PADRE with... Doxorubicin + C... | 18 Years - | University of Arkansas | |
| Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry | NCT02302742 | Breast Cancer Hereditary Brea... | - | University of Kansas Medical Center | ||
| A Study of SGN-PDL1V in Advanced Solid Tumors | NCT05208762 | Carcinoma, Non-... Squamous Cell C... Esophageal Squa... Ovarian Neoplas... Melanoma Triple Negative... Gastric Cancer | SGN-PDL1V pembrolizumab | 18 Years - | Seagen Inc. | |
| Study of Eribulin in Combination With Anti-PD-1 Antibody in Patients With Metastatic Triple-Negative Breast Cancer | NCT05402722 | TNBC - Triple-N... | Eribulin anti-PD-1 antib... | 18 Years - 75 Years | Beijing 302 Hospital | |
| First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours | NCT04504669 | Clear Cell Rena... Non-Small-Cell ... Triple Negative... Squamous Cell C... Small Cell Lung... Gastroesophagea... Melanoma Cervical Cancer Advanced Solid ... | AZD8701 Durvalumab | 18 Years - 101 Years | AstraZeneca | |
| Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer | NCT05113966 | Triple Negative... | Trilaciclib Sacituzumab Gov... | 18 Years - | G1 Therapeutics, Inc. | |
| SHR-A1921 Combined With Bevacizumab in Triple-negative Breast Cancer With Brain Metastases | NCT06210438 | TNBC Brain Metastasi... | SHR-A1921 + Bev... | 18 Years - | Fudan University | |
| A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors | NCT02222922 | Neoplasms | PF-06647020 Q3W fluconazole PF-06647020 Q2W PF-06647020 com... | 18 Years - | Pfizer | |
| A Study Of PF-06647263 In Patients With Advanced Solid Tumors | NCT02078752 | Neoplasms Triple-Negative... | PF-06647263 PF-06647263 | 18 Years - | Pfizer | |
| Eribulin in mTNBC Patients | NCT04541420 | Breast Cancer | - | Fudan University | ||
| Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors | NCT02307240 | Triple-Negative... High-grade Sero... Solid Tumors NUT Midline Car... | CUDC-907 | 16 Years - | Curis, Inc. | |
| Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer | NCT04768426 | Triple Negative... Breast Cancer | Capecitabine | 18 Years - | Stanford University | |
| A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors | NCT04577963 | Triple Negative... Endometrial Can... Solid Tumor, Un... Colorectal Canc... | Fruquintinib Tislelizumab | 18 Years - | Hutchmed | |
| NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III) | NCT06081244 | Triple Negative... | Sacituzumab gov... Pembrolizumab | 18 Years - | West German Study Group | |
| A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors | NCT02222922 | Neoplasms | PF-06647020 Q3W fluconazole PF-06647020 Q2W PF-06647020 com... | 18 Years - | Pfizer | |
| Surufatinib Combined With Tislelizumab in the Second-line and Further Treatment of Triple-negative Breast Cancer | NCT05746728 | Metastatic Trip... | Surufatinib Tislelizumab | 18 Years - | Tongji Hospital | |
| GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma | NCT04060342 | Pancreatic Aden... Esophageal Aden... Esophageal Squa... Gastric Adenoca... Gastroesophagea... Triple Negative... Castration-resi... Microsatellite ... Non-small Cell ... Small-cell Lung... Head and Neck S... Urothelial Carc... Renal Cell Carc... Hepatocellular ... | GB1275 nab-paclitaxel ... pembrolizumab | 18 Years - | Gossamer Bio Inc. | |
| A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors | NCT05581004 | Locally Advance... NSCLC HNSCC Melanoma TNBC Esophageal Canc... Gastric Cancer Cervical Cancer Urothelial Carc... Clear Cell RCC HCC | RO7502175 Atezolizumab | 18 Years - | Genentech, Inc. | |
| Study of CB-839 in Combination w/ Paclitaxel in Participants of African Ancestry and Non-African Ancestry With Advanced Triple Negative Breast Cancer (TNBC) | NCT03057600 | Triple Negative... TNBC - Triple-N... | Paclitaxel CB-839 | 18 Years - | Calithera Biosciences, Inc | |
| PQR309 and Eribulin in Metastatic HER2 Negative and Triple-negative Breast Cancer (PIQHASSO) | NCT02723877 | Metastatic Brea... | PQR309 Eribulin | 18 Years - | PIQUR Therapeutics AG | |
| ctDNA Based MRD Testing for NAC Monitoring in TNBC | NCT06230185 | TNBC - Triple-N... Minimal Residua... | 18 Years - | Personalis Inc. | ||
| AR-inhibitor Bicalutamide in Treating Patients With TNBC | NCT02353988 | Breast Neoplasm... | Bicalutamide Physician's Cho... | 18 Years - 70 Years | Jinling Hospital, China | |
| A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. | NCT06022029 | Triple Negative... Diffuse Large B... Follicular Lymp... Lymphoma, Non-H... Mantle Cell Lym... Bladder Cancer Uveal Melanoma,... Cervix Cancer Carcinoma in Si... Head and Neck S... Skin Cancer Metastatic Canc... Tumor, Solid Tumor Recurrenc... | ONM-501 Cemiplimab | 18 Years - | OncoNano Medicine, Inc. | |
| A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies | NCT03329950 | Melanoma Non-small Cell ... Breast Cancer Gastric Cancer Renal Cell Carc... Ovarian Cancer Cholangiocarcin... Bladder Urothel... Pancreatic Aden... Colorectal Canc... Esophageal Canc... Hepatic Cancer Head and Neck C... Primary Periton... Fallopian Tube ... Other Solid Tum... Diffuse Large B... Mantle Cell Lym... Indolent B-cell... Non-Hodgkin Lym... Follicular Lymp... Lymphoplasmacyt... Waldenstrom's D... Marginal Zone L... Mucosa Associat... Small Lymphocyt... | CDX-1140 CDX-301 pembrolizumab Chemotherapy | 18 Years - | Celldex Therapeutics | |
| A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors | NCT04725331 | Metastatic Canc... Soft Tissue Sar... Merkel Cell Car... Melanoma Triple Negative... Non Small Cell ... | BT-001 Pembrolizumab [... | 18 Years - | Transgene | |
| GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma | NCT04060342 | Pancreatic Aden... Esophageal Aden... Esophageal Squa... Gastric Adenoca... Gastroesophagea... Triple Negative... Castration-resi... Microsatellite ... Non-small Cell ... Small-cell Lung... Head and Neck S... Urothelial Carc... Renal Cell Carc... Hepatocellular ... | GB1275 nab-paclitaxel ... pembrolizumab | 18 Years - | Gossamer Bio Inc. | |
| Cisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC) | NCT02393794 | Triple-Negative... Breast Cancer | Romidepsin Cisplatin Nivolumab | 18 Years - | University of Kansas Medical Center | |
| ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma | NCT03394027 | Triple Negative... Endometrial Can... Hormone Recepto... | ONC201 | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies | NCT03719326 | TNBC - Triple-N... Ovarian Cancer | Etrumadenant IPI-549 Pegylated lipos... nanoparticle al... | 18 Years - | Arcus Biosciences, Inc. | |
| Surufatinib Combined With Tislelizumab in the Second-line and Further Treatment of Triple-negative Breast Cancer | NCT05746728 | Metastatic Trip... | Surufatinib Tislelizumab | 18 Years - | Tongji Hospital | |
| A Study to Evaluate Gemcitabine Plus Cisplatin in the Treatment of TNBC Patients Following Neoadjuvant Chemotherapy | NCT04297267 | Triple Negative... | Gemcitabine Cisplatin | 18 Years - 70 Years | Fudan University | |
| Reverse Triple Negative Immune Resistant Breast Cancer | NCT05076682 | Triple-negative... | Choline anti-PD-1 antib... Sodium Cromogli... Efavirenz | 18 Years - 70 Years | Fudan University | |
| the Role of Two Different Metronomic Chemotherapy Regimens in Locally Advanced or Metastatic Triple Negative Breast Cancer Patients (TNBC) as Maintenance Therapy After First Line Treatment | NCT03358004 | Triple Negative... | Vinorelbine Tar... Capecitabine 50... | 18 Years - | Mario Negri Institute for Pharmacological Research | |
| Study to Compare a Mono Atezolizumab Window Followed by a Atezolizumab - CTX Therapy With Atezolizumab - CTX Therapy | NCT04770272 | Triple-negative... | Atezolizumab 84... Atezolizumab 12... Carboplatin Paclitaxel Epirubicin Cyclophosphamid... Biopsy Arm A Biopsy Arm B Surgery | 18 Years - | Palleos Healthcare GmbH | |
| A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors | NCT05941507 | Advanced Solid ... | LCB84 Anti-PD-1 monoc... | 18 Years - | LigaChem Biosciences, Inc. | |
| A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat | NCT02890069 | Colorectal Canc... | PDR001 LCL161 Everolimus Panobinostat QBM076 HDM201 | 18 Years - | Novartis | |
| LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer | NCT06387628 | TNBC - Triple-N... | LM-108 Toripalimab Eribulin Nab paclitaxel | 18 Years - 75 Years | Fudan University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
